IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. - Wikidata - awgldk - TriplyDB

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

http://www.wikidata.org/entity/Q37381182

about

Predictive biomarkers in precision medicine and drug development against lung cancer IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?FAK in cancer: mechanistic findings and clinical applications Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway.IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin.Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity.Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment.Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.Invasion-Related Factors as Potential Diagnostic and Therapeutic Targets in Oral Squamous Cell Carcinoma-A Review.Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.

P2860

Q26824536-072ED2AB-3FD6-407F-8147-43EA2889EC57 Q27003443-5711C83A-CDC2-42D9-8C9C-817A5D065E0E Q27026533-6B42F294-4EB4-4716-9298-05F89AE1AFBA Q28550689-587DED04-A8BA-477F-9122-4EF6F9BA0EE2 Q33829595-EDF95320-DBBE-4925-9655-F70F8D0E0FDB Q35606589-395C57C3-7831-4B2F-AAF2-3887468AC5EA Q36336487-73D9D69D-4684-4B48-BDB9-F963798C3BDA Q36413323-877D5707-C8F2-4136-B3BC-E7FACE3705EC Q36772192-067BC4BE-42E7-42D3-A09F-630FC49DD36C Q37589930-15293380-F660-449A-8E9B-824896601F91 Q37725641-81F32B72-DDDB-484D-A222-3D7771E676BC Q38607782-699DC366-22C1-496A-937E-B0722D6A262D Q38667847-34AD234B-AAF1-4063-9312-0109AE2B766B Q38854580-A542E1BC-BB23-4957-9B91-7CFDFD65F1F4 Q42365291-76888730-0E7F-4A14-AF01-E0E572AC62E7 Q42778341-982E5CFC-42CF-42D1-9AED-5BC874D6642B Q47861796-F4DE7262-6B92-4950-A2DB-5AF53744FCCD Q48864865-E51A6DCC-5CD1-44DC-9BF5-09D720A64A44 Q52837987-65FF0DC2-AC7B-4DB4-AB1C-94EE17A3F123 Q54957173-C54CCAF0-2AFD-463D-96C9-C5B8439FD31E Q54966612-054BE32F-62AD-4D26-9F2D-7F5B3C67E6AD

P2860

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

http://www.wikidata.org/entity/Q37381182

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@en

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@nl

type

label

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@en

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@nl

prefLabel

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@en

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@nl

P1433

Q37381182-CA084EE4-0B52-4A1E-B748-6A7015FCB250

P1476

Q37381182-69398B99-D114-499B-9279-1FD695212872

P2093

Q37381182-33B95131-72A6-462F-A5FF-1D4410CA71D0

Q37381182-386CECD9-6C9E-4E60-8C5B-AF422CED3915

Q37381182-39F10AA0-3A62-46D0-B059-18B471B4196A

Q37381182-805D0359-AB7B-45E6-9748-C1C9D01BCF86

Q37381182-85895327-4249-4187-BDBC-DBAA0343E029

Q37381182-B61CC5EE-DAA8-4BBD-B95B-1BB5AF02E7C6

Q37381182-BAC4F1A0-D16A-4F11-84FE-2333A2B76396

Q37381182-CAACF0F7-3479-44D2-BDED-F4E6141B10CB

Q37381182-D272EB04-CB06-4E99-AE1C-310848013F7C

Q37381182-DB956A5A-FEEA-49EC-A04A-9C76A48CF4CA

P2860

Q37381182-04892F78-F7D0-4CC3-9800-4C285C5E0FAE

Q37381182-20A6DBB6-F116-4197-B708-93103F0A3103

Q37381182-26ED4C2D-2D2B-4261-8173-7E11852BF7B0

Q37381182-2C566AFA-8496-423B-92C6-2CDAFE4A3D92

Q37381182-31D89734-BDAE-4986-A767-FDA9A9A4BA0E

Q37381182-3D3678D6-9A9A-4E0B-B6F6-52B193DC6A6A

Q37381182-426470BB-6493-4C09-A3D1-10A60041B0F9

Q37381182-4D94C8D9-78C6-490D-B7B0-B665F1F9C6C4

Q37381182-4DB34935-62F2-4513-96CA-201776E165F1

Q37381182-55F90A2F-D512-4261-B4CD-D62912EE6F1B

P304

Q37381182-11A91F69-D218-4758-B483-068E329245FD

P31

Q37381182-FD65BAC9-5845-4F60-AE72-5C9A4DDA823C

P356

Q37381182-9DA60AD0-2166-4A96-B62D-23A3210F2007

P433

Q37381182-66497DB6-A139-424B-9BC2-FE029BDE4435

P478

Q37381182-E30F1E77-D124-4ACC-8FB9-C80407D2B332

P577

Q37381182-079B8632-7F8A-4D9C-B038-0A81604576B2

P698

Q37381182-542C50E7-6A55-4871-A86C-9038C29E6868

P932

Q37381182-74FCD32B-827B-4115-A4EE-6875490249B2

P356

1535-7163.MCT-13-0233

P1433

Molecular Cancer Therapeutics

P1476

IGFBP2/FAK pathway is causally ...... -small cell lung cancer cells.

@en

P2093

Bingbing Dai

http://www.w3.org/2001/XMLSchema#string

Bingliang Fang

http://www.w3.org/2001/XMLSchema#string

Haibo Lu

http://www.w3.org/2001/XMLSchema#string

Jack A Roth

http://www.w3.org/2001/XMLSchema#string

Jieru Meng

http://www.w3.org/2001/XMLSchema#string

John Minna

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Shuhong Wu

http://www.w3.org/2001/XMLSchema#string

Stephen G Swisher

http://www.w3.org/2001/XMLSchema#string

Wayne L Hofstetter

http://www.w3.org/2001/XMLSchema#string

P2860

Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Signalling via integrins: implications for cell survival and anticancer strategies

Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

P304

2864-2873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-13-0233

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24130049

http://www.w3.org/2001/XMLSchema#string

P932

3858413

http://www.w3.org/2001/XMLSchema#string